Latest news with #CSL
The Hindu
2 days ago
- Business
- The Hindu
Keel laying of eighth anti-submarine warfare ship held
The keel laying of the eighth anti-submarine warfare (ASW) ship being built for the Indian Navy was held at Cochin Shipyard Limited (CSL) by Vice Admiral Rajaram Swaminathan, Controller of Warship Production and Acquisition, on May 29, 2025. Among those present were Madhu S. Nair, Chairman and Managing Director, CSL, and Rear Admiral Vishal Bishnoi, Assistant Controller of Warship Production and Acquisition. The contract for building eight ASW ships was signed between the Ministry of Defence (MoD) and CSL on 30 April 2019. The Mahe class of ships will replace the in-service Abhay class ASW corvettes of the Indian Navy and are designed to undertake anti-submarine operations in coastal waters, low-intensity maritime operations, mine-laying operations, and subsurface surveillance. The vessels are capable of a maximum speed of 25 knots and have an endurance of 1,800 nautical miles. They are fitted with indigenously developed, state-of-the-art sonars for underwater surveillance. This exemplifies India's capability to manufacture high-end, technology-intensive warships with a high indigenous content under the 'Aatmanirbhar Bharat' initiative.
Sky News AU
3 days ago
- Business
- Sky News AU
Jim Chalmers resorting to new taxes is a misguided attempt to ‘purchase prosperity' as private investment in the Australian economy crashes
Earlier this month, a collapsed high-voltage wire near Strathfield Station brought Sydney's entire railway network to a halt, forcing commuters to endure days of chaos and delay. The State Government and rail officials scrambled to apologise, offering a fare-free travel day as compensation. But no number of free rides can repair the ancient cabling, rigid work practices, and flawed design that make the city's rail system so fragile. Sydney's rail meltdown is more than a transport failure - it is a metaphor for Australia's broader political and economic malaise. A system that appears to function smoothly on the surface is merely running on inertia. Beneath the facade lies decay: decades of short-termism, underinvestment, and complacency. This week's news that business investment is falling confirms the rot has spread to the foundations of the national economy and that the current government has little appetite for structural reform. Non-mining investment contracted by 1.6 per cent nationally in the March quarter, while private capital expenditure dropped by 5.3 per cent in Victoria in the three months to March. Yet private investment is the engine of job creation, productivity, and wage growth. Without it, the reverse holds: business shrinks, employment stagnates, and economic momentum falters. Capital - the lifeblood of any economy - flows to where it is welcomed and where returns are reliable. Under Treasurer Jim Chalmers, businesses are increasingly wary of investing in Australia, deterred by high costs, regulatory burdens, and policy uncertainty. The Albanese government's Future Made in Australia strategy risks remaining a slogan unless it can reverse this investment drought. But rising energy costs and an increasingly unreliable power supply are driving manufacturers offshore. On top of that, Australia's high labour costs and complex industrial relations system deter new ventures. CSL Chairman Brian McNamee captured the mood when he said businesses were reacting to 'an accumulation of hostile policies and government crowding out of enterprise'. Investment capital, he warned, 'will find homes elsewhere that are more welcoming and reward risk-taking'. These cracks in our economic edifice didn't appear overnight. Like Sydney's ageing power lines and outdated rolling stock, the deterioration has been years in the making. Australia's GDP per capita has now declined for seven consecutive quarters - a sign that, were it not for population growth through immigration, the country would be in recession. Productivity, the key driver of long-term prosperity, has flatlined. Over the past two decades, it has grown at just 0.7 per cent per year. In the last year, growth was a mere 0.5 per cent. Small wonder that living standards have been slipping since the pandemic. Whatever growth the economy shows is increasingly the product of government spending - now at 27 per cent of GDP, up two points from pre-COVID levels. But governments cannot purchase prosperity any more than they can restore a rail system with free travel days. Eventually, they resort to new taxes. Mr Chalmers' proposal to tax unrealised capital gains in superannuation is one such example - a measure that will discourage long-term savings and further undermine private investment. Self-managed super funds, often used to back small business and start-ups, will be particularly affected. For a cautionary tale, we need only look to Germany, a country long admired for its engineering excellence and export-driven economy. But as Wolfgang Münchau explains in 'Kaputt: The End of the German Miracle ' , complacency and underinvestment have taken their toll. Germany's efficiency endured as a reputation long after it disappeared as a rea lity. The nation failed to keep pace with the digital era, relying instead in analogue infrastructure and unreliable energy sources. Dependence on Russian gas and costly renewables sent electricity prices soaring - now among the highest in Europe. Meanwhile, Germany's vaunted rail system has become a symbol of national decline. Deutsche Bahn, once synonymous with precision and quality, is now plagued by delays, technical faults, and overcrowding. In 2024, just 62 per cent of long-distance trains arrived on time. In April, Swiss operator SBB cut two cross-border services, fearing Germany's dysfunction would spill over into their own network. The parallels with Australia are sobering. Both nations rode waves of prosperity driven by commodity exports while neglecting the need for reform. Both now face the consequences: rigid regulatory systems, soaring power prices, stagnant productivity, and eroded competitiveness. And in both countries, the signs of decline were ignored until something broke. Germany kept betting against the digital age. Australia, too, risks believing its own myth of resilience and economic strength, long after the underlying conditions have shifted. If we don't act now to address structural weaknesses, the next broken wire, literal or metaphorical, will leave more than just a railway in chaos. Nick Cater is a senior fellow at Menzies Research Centre and a regular contributor to Sky News Australia
Yahoo
27-05-2025
- Business
- Yahoo
1 Cash-Producing Stock with Exciting Potential and 2 to Be Wary Of
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Luckily for you, we built StockStory to help you separate the good from the bad. That said, here is one cash-producing company that excels at turning cash into shareholder value and two that may face some trouble. Trailing 12-Month Free Cash Flow Margin: 29.3% Boasting major consumer staples and pharmaceutical companies as clients, Manhattan Associates (NASDAQ:MANH) offers a software-as-service platform that helps customers manage their supply chains. Why Do We Pass on MANH? Average billings growth of 3.6% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand Estimated sales growth of 1.9% for the next 12 months implies demand will slow from its three-year trend Gross margin of 55.6% is way below its competitors, leaving less money to invest in areas like marketing and R&D At $185.23 per share, Manhattan Associates trades at 10.6x forward price-to-sales. Check out our free in-depth research report to learn more about why MANH doesn't pass our bar. Trailing 12-Month Free Cash Flow Margin: 15.5% Originally founded as Carlisle Tire and Rubber Company, Carlisle Companies (NYSE:CSL) is a multi-industry product manufacturer focusing on construction materials and weatherproofing technologies. Why Does CSL Worry Us? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Anticipated sales growth of 5.1% for the next year implies demand will be shaky Earnings growth underperformed the sector average over the last two years as its EPS grew by just 4.8% annually Carlisle's stock price of $386.84 implies a valuation ratio of 17.1x forward P/E. If you're considering CSL for your portfolio, see our FREE research report to learn more. Trailing 12-Month Free Cash Flow Margin: 25.7% Short for microcomputer software, Microsoft (NASDAQ:MSFT) is the largest software vendor in the world with its Windows operating system, Office suite, and cloud computing services. Why Are We Backing MSFT? Microsoft is one of the great brands not just in tech but all of business. It produces mission-critical software and bundles it together, resulting in cream-of-the-crop gross margins. The company's elite unit economics lead to robust profit margins that improve over time. This speaks to the scale advantages and operating efficiency across its diverse portfolio, which spans everything from Office and Azure to Minecraft. Microsoft has a virtuous cycle of returns. Its dominant market position enables it to generate strong free cash flow, and it reinvests these funds into promising ventures that further strengthen its competitive moat. Microsoft is trading at $450.33 per share, or 31.7x forward price-to-earnings. Is now a good time to buy? Find out in our full research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free.
Yahoo
26-05-2025
- Business
- Yahoo
CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
CSL saw its stock price rise by 3% over the last month, amid important developments and a fluctuating market environment. CSL Vifor's notable progress with the National Institute for Health and Care Excellence recommending sparsentan for primary IgA nephropathy treatment may have provided positive momentum. This significant medical endorsement, alongside CSL's continued engagement with shareholders through meetings, could have added weight to its share performance. Meanwhile, broader market volatility, influenced by global trade tensions and declining major indexes, may have tempered the extent of CSL's gains, which align closely with general market movement, as the market faced a 1% decline. We've spotted 1 possible red flag for CSL you should be aware of. The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. The recent developments regarding CSL's approval for sparsentan, a treatment recommended by the National Institute for Health and Care Excellence, may enhance the company's market position, potentially fueling revenue growth. Over the past three years, however, CSL's total return, inclusive of share price changes and dividends, recorded a decline of 4.64%. This contrasts against a broader 1-year underperformance both relative to the Australian market's 4.9% increase and the Australian Biotechs industry's -9.4% decrease, highlighting a need to bridge the performance gap with new advancements. Looking forward, the impact of these medical endorsements might influence CSL's revenue and earnings forecasts positively, with anticipated expansion in the HAE and vaccine sectors playing a crucial role. Despite the current share price of A$251.13 being lower than the consensus analyst price target of A$311.94, suggesting a potential upswing, the market's fluctuations must be considered in investment evaluations. As CSL continues to hone operational efficiencies and product rollouts, assessing these factors against earnings projections will be vital in understanding its long-term trajectory. According our valuation report, there's an indication that CSL's share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:CSL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
News.com.au
21-05-2025
- Health
- News.com.au
Aussie researchers and ASX biotechs driving paediatric drug breakthroughs
Australia has become well-known for its paediatric drug discovery with several life-altering treatments CSL is a global leader in developing therapies for children with haemophilia and other serious blood disorders Neurotech International is at forefront of developing cannabinoid-derived therapies for paediatric neurological disorders Australia may lack the size and funding of larger global biotech hubs, but it consistently punches above its weight in paediatric drug discovery. From life-altering treatments for rare genetic conditions to vaccines that have reshaped public health, Aussie researchers and ASX-listed companies have and continue to deliver breakthroughs improving and in some cases saving young lives globally. Among these advancements is Australia's largest biotech CSL (ASX:CSL), which has become a global leader in developing therapies for children with haemophilia and other serious blood disorders. Its paediatric haemophilia products — including Afstyla and Hemlibra — allow young patients to live more freely and safely. CSL also played a pivotal role in bringing Gardasil to the world – the revolutionary human papillomavirus (HPV) vaccine co-developed by former Australian of the Year Professor Ian Frazer at the University of Queensland. The vaccine is helping to protect millions of girls and boys from HPV-related cancers. In the 1990s Dr Sandra Anderson and colleagues at Sydney's Royal Prince Alfred Hospital (RPAH) started research into how inhaled mannitol can be used to diagnose asthma. Their work resulted in development of two new pharmaceutical products: • Aridol – to identify bronchial hyperresponsiveness and assist in asthma diagnosis. • Bronchitol – to treat patients with bronchiectasis and cystic fibrosis (CF) by helping clear mucus from their lungs. In 2001 Pharmaxis now Syntara (ASX:SNT) licensed patents for respiratory products from the Central Sydney Area Health Service (which included RPAH). Pharmaxis funded later stage clinical trials necessary to get Aridol and Bronchitol, which are now available world-wide, approved. Its shares peaked in 2007 at over $4 a share – for a roughly $800 million market cap – mainly on its Bronchitol hopes. The company announced sale of its mannitol respiratory unit, which included Aridol and Bronchitol, in October 2023 along with its rebrand to Syntara and change of focus to haematological malignancies. On the ASX, several healthcare players are cooking up the next-gen of paediatric therapeutics. Neuren targets various rare diseases In 2023 Neuren Pharmaceuticals (ASX:NEU) became the darling of the Aussie bourse after its US partner Acadia Pharmaceuticals secured US Food and Drug Administration (FDA) approval for trofinetide to treat Rett syndrome. Marketed as Daybue, it is the first drug to treat the rare neurological disorder which emerges in infancy and is a profoundly debilitating neurological condition affecting predominately girls. And Neuren hasn't stopped there. It's also advancing NNZ-2591 in clinical trials for a suite of other rare paediatric syndromes – including Angelman, Phelan-McDermid, and Pitt-Hopkins — for which there are currently no approved treatments options. Neuren is also developing NNZ-2591 to treat neonatal hypoxic-ischemic encephalopathy (HIE). "HIE is a devastating type of brain injury caused when a baby's brain does not receive enough oxygen or blood flow before or shortly after birth," CEO and managing director Jon Pilcher told Stockhead. "It is one of the leading causes of neonatal death and neurodevelopmental disability. He said Neuren aimed to provide a highly differentiated form of treatment continuing beyond the neonatal intensive care unit to target the long-term outcomes for these children. "Neuren's whole business is aimed at trying to improve the lives of the children and their families that are so impacted by all of these conditions," he said. "The whole team is highly motivated by that mission, building on scientific foundations from Australia and New Zealand." Argenica Therapeutics (ASX:AGN) has been targeting neonatal HIE for nearly a decade, alongside other acute neurological conditions such as stroke and traumatic brain injury, with its novel therapeutics aimed at reducing brain tissue death. Its first published paper out of the Perron Institute in Western Australia was in 2018. The study was run by Dr Adam Edwards, who leads Argenica's preclinical neonatal HIE program. Both Argenica's therapeutic candidates ARG-006 and ARG-007 are being investigated for their respective safety and efficacy profiles in HIE, offering different therapeutic options for the treatment of the condition. The FDA has granted both ARG-006 and ARG-007 ODD and Rare Paediatric Disease Designations (RPDD), qualifying Argenica for significant incentives. Neurotech tackles paediatric neuro disorders Neurotech International (ASX:NTI) is at the forefront of developing cannabinoid-derived therapies for paediatric neurological disorders, led by its proprietary oral formulation, NTI164. Derived from a unique cannabis strain with ultra-low THC ( Following the path of successful companies like Neuren, Neurotech is advancing treatments for Rett syndrome, having completed a phase I/II trial with promising results and an extension study currently underway. NTI164 has been granted orphan drug designation (ODD) by both the US FDA and the European Commission, reinforcing its potential as a differentiated therapy in this rare disease. Beyond Rett, Neurotech has completed multiple paediatric clinical programs with NTI164, including: • A phase I/II and phase II/III trial in Autism Spectrum Disorder (ASD) • Phase I/II trials in PANDAS/PANS (Paediatric Autoimmune Neuropsychiatric Disorders and Acute-Onset Neuropsychiatric Syndrome) "Neurotech is redefining the potential of cannabinoid-derived therapies in paediatric neurology," newly appointed CEO and managing director Dr Anthony Filippis told Stockhead. "With NTI164, we're not just targeting symptoms, we're aiming to shift the treatment paradigm for conditions like Rett syndrome, ASD, and PANDAS/PANS. "The orphan drug designations in the US and Europe affirm the unique promise of our approach, and we're committed to advancing NTI164 towards approval and access for the families who need it most." Dimerix tackles leading cause of kidney failure in children Dimerix (ASX:DXB) is focused on the rare kidney disease focal segmental glomerulosclerosis (FSGS) with its lead phase III drug candidate DMX-200. CEO and managing director Dr Nina Webster told Stockhead FSGS affects both adults and children damaging filtering units of the kidneys, leading to permanent damage and eventual organ failure. 'FSGS is one of the leading causes of kidney failure in children, with 20% of all presentations of nephrotic syndrome in paediatric patients caused by the disease,' she said. 'This is a disease for which there are no treatments available anywhere in the world and 60% of those who do get a transplant get reoccurring disease in the transplanted kidney. 'This is a very poor prognosis and in particular for children who will live with life-long dialysis.' Dimerix's phase III study of lead drug DMX-200 in FSGS is titled Angiotensin II Type 1 Receptor (AT1R) & Chemokine Receptor 2 (CCR2) Targets for Inflammatory Nephrosis – or ACTION3 for short. The second interim analysis of its ACTION3 trial is forecast in around mid-CY25. DMX-200 has been granted ODD in the US and Europe, as well as the equivalent Innovative Licensing and Access Pathway (ILAP) designation in the UK. Mesoblast gains world-first approval for treatment Mesoblast (ASX:MSB) has developed Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in paediatric patients two months and older, which is the first FDA approved mesenchymal stromal cell (MSC) therapy. Resulting from bone marrow transplants, GvHD is a life-threatening condition with high mortality rates. Mesoblast said in the US about 10,000 patients undergo a bone marrow transplant annually with donated tissue, 1500 of whom are children. About half of them will develop GvHD and 50% of these won't respond to steroids. Ryoncil applies to patients resistant to steroids, the standard-of-care treatment. Mesoblast is also targeting the children's disorder hypoplastic left heart syndrome, for which it has rare paediatric disease designation from the US FDA for its allogeneic cell therapy Revascor.
